A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.Giuseppe Giaccone, Herbert M. Pinedo, Cornelis J. A. Punt et al.|PubMed|2002Cited by 507
Clinical Pharmacokinetics of CyclophosphamideMilly E. de Jonge, Jos H. Beijnen, Alwin D. R. Huitema et al.|Clinical Pharmacokinetics|2005Cited by 451
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M. Henricks, Jan H.M. Schellens, Helga Droogendijk et al.|The Lancet Oncology|2018Cited by 419
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.Manon Huizing, Jos H. Beijnen, Anther Keung et al.|Journal of Clinical Oncology|1993Cited by 313
Taxanes: A New Class of Antitumor AgentsManon Huizing, Jos H. Beijnen, Vinoj H Sewberath Misser et al.|Cancer Investigation|1995Cited by 283